What is Oppenheimer's price target for BPMC?

Oppenheimer's latest stated price target for Blueprint Medicines Corporation (BPMC) is $85, from its action on Oct 27, 2023.

What is Oppenheimer's rating on BPMC?

Oppenheimer rates BPMC Outperform, a bullish rating, as of Oct 27, 2023.

When did Oppenheimer last change its view on BPMC?

On Oct 27, 2023, Oppenheimer upgrades to Outperform from Perform, price target $85.

Analyst firms · Oppenheimer · BPMC

Oppenheimer BPMC price target and rating history

Blueprint Medicines Corporation (BPMC) · Health Care

Oppenheimer rates Blueprint Medicines Corporation (BPMC) Outperform with a $85 price target, as of its latest action on Oct 27, 2023. It has published 3 rating actions on BPMC since July 2022, including 1 upgrade and 1 downgrade.

Current rating: Outperform
Price target: $85
Median target, all firms: Too few
Actions on BPMC: 3

Oppenheimer price target on BPMC

Oppenheimer price target on BPMC, each point a stated target, July 2022 to October 2023.

Every Oppenheimer rating on BPMC

Oct 27, 2023
UpgradeOppenheimer upgrades to Outperform from Perform, price target $85
Nov 2, 2022
DowngradeOppenheimer downgrades to Perform from Outperform
Jul 8, 2022
InitiateOppenheimer starts coverage at Outperform, price target $80

Questions about Oppenheimer and BPMC

What is Oppenheimer's price target for BPMC?: Oppenheimer's latest stated price target for Blueprint Medicines Corporation (BPMC) is $85, from its action on Oct 27, 2023.
What is Oppenheimer's rating on BPMC?: Oppenheimer rates BPMC Outperform, a bullish rating, as of Oct 27, 2023.
When did Oppenheimer last change its view on BPMC?: On Oct 27, 2023, Oppenheimer upgrades to Outperform from Perform, price target $85.

More BPMC rating histories

All Oppenheimer ratings BPMC news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.